Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination

Blood. 2022 Dec 1;140(22):2403-2407. doi: 10.1182/blood.2022016815.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Humans
  • Immunocompromised Host
  • Leukemia, Lymphocytic, Chronic, B-Cell* / complications
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination

Substances

  • RNA, Messenger
  • Antibodies, Viral